{
  "id": 10448284,
  "title": "Merck, Daiichi end plans to seek speedy approval of lung cancer ADC",
  "url": "https://urgent.news/2026/09/28/merck-daiichi-end-plans-to-seek-speedy-approval-of-lung-cancer-adc",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-28T12:52:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/merck-daiichi-fda-withdraw-ifinatamab-deruxtecan-sclc/831440/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Daiichi Sankyo and Merck withdraw lung cancer drug application",
        "url": "https://urgent.news/2026/09/25/daiichi-sankyo-and-merck-withdraw-lung-cancer-drug-application",
        "published": "2026-09-25T20:36:34.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}